18558882. DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS simplified abstract (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM)
Contents
DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS
Organization Name
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventor(s)
Kytai Nguyen of Austin TX (US)
Serkan Yaman of Austin TX (US)
Harish Ramachandramoorthy of Arlington TX (US)
Manoj Kumar Sabnani of Arlington TX (US)
DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18558882 titled 'DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS
- Simplified Explanation:**
The patent application describes CAR-T MNP compositions and methods for targeted therapeutic delivery using engineered T lymphocyte membrane-coated nanoparticles.
- Key Features and Innovation:**
- Chimeric antigen receptor (CAR) engineered T lymphocyte membrane-coated nanoparticles.
- Targeted delivery of therapeutics to specific targets.
- Utilizes the unique properties of T lymphocytes for drug delivery.
- Potential Applications:**
The technology can be used in targeted drug delivery for various diseases such as cancer, autoimmune disorders, and infectious diseases.
- Problems Solved:**
The technology addresses the challenge of targeted drug delivery to specific cells or tissues while minimizing off-target effects.
- Benefits:**
- Enhanced precision in drug delivery.
- Reduced side effects.
- Improved therapeutic outcomes.
- Commercial Applications:**
The technology has potential applications in the pharmaceutical industry for developing targeted therapies and personalized medicine approaches.
- Questions about CAR-T MNP:**
1. How does the engineered T lymphocyte membrane enhance the targeted delivery of therapeutics? 2. What are the potential limitations of using CAR-T MNP technology in clinical settings?
Original Abstract Submitted
Disclosed are chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNP) compositions and methods of using the same for delivering therapeutics to a particular target.
